RxDoctor Payments Data

Adrian de Castro-Quiros, MD

Psychiatry · Miami, FLNPI 1144614660

Payments from drug & device makers

$11,691in general payments, 2019–2025

Across 479 payments — averaging $24.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Sunovion Pharmaceuticals Inc.$1K
  • Axsome Therapeutics, Inc.$1K
  • Eisai Inc.$876
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$820
  • plus $3K from 13 others

What the payments were for

  • Food & beverage$11,691100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,691 in reported general payments places this provider in the 85th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$114,884
Medicare patients
168
Services billed
1,185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide171$90,236
NuplazidPimavanserin Tartrate14$68,631
VraylarCariprazine Hcl27$47,262
BelsomraSuvorexant74$32,452
NamzaricMemantine Hcl/Donepezil Hcl38$29,125
Aripiprazole446$22,443
LybalviOlanzapine/Samidorphan Malate11$19,626
Quetiapine Fumarate1,392$17,593
Venlafaxine Hcl ErVenlafaxine Hcl782$9,949
LunestaEszopiclone11$9,854
Clonazepam1,375$9,714
Olanzapine217$7,672
Mirtazapine615$6,718
Doxepin Hcl135$6,595
Bupropion XlBupropion Hcl425$6,250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$1,300$90,236171 claims
AbbVieVraylar, Namzaric, Fetzima$3,221$82,22077 claims
Acadia Pharmaceuticals IncNuplazid$224$68,63114 claims
MerckBelsomra$43$32,45274 claims
Alkermes, Inc.Lybalvi$150$19,62611 claims
Almatica Pharma LLCSertraline Hcl$121$3,054861 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →